Compare TYRA & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | BW |
|---|---|---|
| Founded | 2018 | 1867 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2021 | 2015 |
| Metric | TYRA | BW |
|---|---|---|
| Price | $25.23 | $7.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $47.50 | $8.00 |
| AVG Volume (30 Days) | 1.0M | ★ 4.2M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.46 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,062,388,000.00 |
| Revenue This Year | N/A | $41.58 |
| Revenue Next Year | N/A | $66.70 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.38 | $2.64 |
| 52 Week High | $40.65 | $22.03 |
| Indicator | TYRA | BW |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 42.58 |
| Support Level | $24.58 | $6.75 |
| Resistance Level | $27.02 | $8.05 |
| Average True Range (ATR) | 2.07 | 0.46 |
| MACD | 0.15 | 0.10 |
| Stochastic Oscillator | 60.09 | 36.00 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.